Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity (Deficit)

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Employees and Directors	Preferred Stock	Common Stock	Preferred Stock	Common Stock	Common Stock Employees and Directors	Additional Paid-In Capital	Additional Paid-In Capital Preferred Stock	Additional Paid-In Capital Common Stock	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2008	$ (3,025,725)					$ 70,863		$ 145,742,044			$ (148,840,015)	$ 1,383
Beginning Balance (in shares) at Dec. 31, 2008						70,862,641
Issued stock in payment of interest on convertible debt and dividends on convertible preferred stock (in shares)						1,393,239
Issued stock in payment of interest on convertible debt and dividends on convertible preferred stock	1,031,333					1,393		1,029,940
Effect of adopting new provisions of FASB ASC Topic 815	(12,961,040)							(8,948,089)			(4,012,951)
Cancelled restricted stock (in shares)						(9,000)
Cancelled restricted stock						(9)		9
Issued stock to 401(k) plan (in shares)						80,883
Issued stock to 401(k) plan	33,473					81		33,392
Issued stock upon exercise of options, net of costs (in shares)						400,441
Issued stock upon exercise of options, net of costs	124,616					400		124,216
Issued stock upon exercise of warrants, net (in shares)						6,948,507
Issued stock upon exercise of warrants, net	6,541,934					6,949		6,534,985
Issued restricted stock (in shares)							1,260,000
Issued restricted stock		1,260					1,260
Effect of change in terms of notes payable, preferred stock and warrants	37,999,312							37,999,312
Stock compensation expense	445,411							445,411
Preferred stock dividends, including deemed dividends	(240,000)										(240,000)
Net income (loss)	(39,605,720)										(39,605,720)
Unrealized loss on available-for-sale securities	(1,383)											(1,383)
Paid issuance costs			(6,323)	(207,000)					(6,323)	(207,000)
Ending Balance at Dec. 31, 2009	(9,869,852)					80,937		182,747,897			(192,698,686)
Ending Balance (in shares) at Dec. 31, 2009						80,936,711
Issued stock in payment of interest on convertible debt and dividends on convertible preferred stock (in shares)						347,832
Issued stock in payment of interest on convertible debt and dividends on convertible preferred stock	476,667					348		476,319
Cancelled restricted stock (in shares)						(4,500)
Cancelled restricted stock						(5)		5
Issued stock to 401(k) plan (in shares)						53,499
Issued stock to 401(k) plan	40,623					53		40,570
Issued stock upon exercise of options, net of costs (in shares)						350,156
Issued stock upon exercise of options, net of costs	(63,705)					350		(64,055)
Issued stock in connection with stock purchase agreement, net of costs (in shares)						660,541
Issued stock in connection with stock purchase agreement, net of costs	777,458					661		776,797
Issued Series B and Series C convertible preferred stock, net of costs (in shares)					11,000
Issued Series B and Series C convertible preferred stock, net of costs	64,636,821				11			64,636,810
Issued restricted stock (in shares)						660,000
Issued restricted stock	660					660
Issued warrants in connection with consulting agreement	279,367							279,367
Issued stock upon exercise of warrants and other (in shares)						157,778
Issued stock upon exercise of warrants and other	316,818					158		316,660
Issued common stock and warrants in connection with direct offering, net of costs (in shares)						3,157,896
Issued common stock and warrants in connection with direct offering, net of costs	4,309,951					3,158		4,306,793
Effect of change in terms of notes payable, preferred stock and warrants	800,878							800,878
Stock compensation expense	597,672							597,672
Preferred stock dividends, including deemed dividends	(8,206,745)										(8,206,745)
Net income (loss)	(49,964,868)										(49,964,868)
Ending Balance at Dec. 31, 2010	4,131,745				11	86,320		254,915,713			(250,870,299)
Ending Balance (in shares) at Dec. 31, 2010					11,000	86,319,913
Cancelled restricted stock (in shares)						(686,000)
Cancelled restricted stock	(596)					(686)		90
Issued stock to 401(k) plan (in shares)						35,233
Issued stock to 401(k) plan	61,971					35		61,936
Issued stock upon exercise of options, net of costs (in shares)						1,832,673
Issued stock upon exercise of options, net of costs	(2,498,223)					1,832		(2,500,055)
Issued stock upon exercise of warrants, net (in shares)						4,026,552
Issued stock upon exercise of warrants, net	8,327,190					4,027		8,323,163
Issued restricted stock (in shares)						872,000
Issued restricted stock	872					872
Effect of change in terms of notes payable, preferred stock and warrants	1,978,818							1,978,818
Conversion of Series B preferred stock to common stock (in shares)					(917)	2,998,590
Conversion of Series B preferred stock to common stock					(1)	2,999		(2,998)
Effect of beneficial conversion feature of promissory note	24,888							24,888
Stock compensation expense	3,592,090							3,592,090
Preferred stock dividends, including deemed dividends	(100,000)										(100,000)
Net income (loss)	5,612,992										5,612,992
Ending Balance at Dec. 31, 2011	$ 21,131,747				$ 10	$ 95,399		$ 266,393,645			$ (245,357,307)
Ending Balance (in shares) at Dec. 31, 2011					10,083	95,398,961